ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show ...

Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...

Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...

Add Yahoo as a preferred source to see more of our stories on Google. Innovation in linkers Antibody-drug conjugate (ADC) developers say innovations to linkers, the proteins bridging antibodies to ...

Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for ...

DUBLIN--(BUSINESS WIRE)--The "Antibody-drug Conjugates: Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. Antibody-drug conjugates (ADCs) are therapies that ...

- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted ...

AMSTERDAM--(BUSINESS WIRE)--Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class ...

Data supporting the rationale for Baylink's innovative ADC linker technology enabling delivery of degraders, dual payload antibody drug conjugates, and high drug to antibody ratio chemotherapy will be ...